| 1 | news publications energy contact | | | | | | | 2 | 0.37% |
| 2 | home clinical studies lh | | | | | | | 2 | 0.37% |
| 3 | clinical studies lh studie | | | | | | | 2 | 0.37% |
| 4 | studies lh studie hcg | | | | | | | 2 | 0.37% |
| 5 | lh studie hcg studie | | | | | | | 2 | 0.37% |
| 6 | studie hcg studie academic | | | | | | | 2 | 0.37% |
| 7 | publications energy contact us | | | | | | | 2 | 0.37% |
| 8 | servicesproducts team news publications | | | | | | | 2 | 0.37% |
| 9 | team news publications energy | | | | | | | 2 | 0.37% |
| 10 | skip to content home | | | | | | | 1 | 0.19% |
| 11 | chemoscale test which tests | | | | | | | 1 | 0.19% |
| 12 | test which tests the | | | | | | | 1 | 0.19% |
| 13 | which tests the effect | | | | | | | 1 | 0.19% |
| 14 | tests the effect of | | | | | | | 1 | 0.19% |
| 15 | effect of 30–60 effective | | | | | | | 1 | 0.19% |
| 16 | the effect of 30–60 | | | | | | | 1 | 0.19% |
| 17 | however there is also | | | | | | | 1 | 0.19% |
| 18 | of 30–60 effective substances | | | | | | | 1 | 0.19% |
| 19 | chemotherapeutic agents in the | | | | | | | 1 | 0.19% |
| 20 | agents in the laboratory | | | | | | | 1 | 0.19% |
| 21 | there is also the | | | | | | | 1 | 0.19% |
| 22 | from blood and optional | | | | | | | 1 | 0.19% |
| 23 | material however there is | | | | | | | 1 | 0.19% |
| 24 | biopsy material however there | | | | | | | 1 | 0.19% |
| 25 | optional biopsy material however | | | | | | | 1 | 0.19% |
| 26 | and optional biopsy material | | | | | | | 1 | 0.19% |
| 27 | blood and optional biopsy | | | | | | | 1 | 0.19% |
| 28 | the laboratory both tests | | | | | | | 1 | 0.19% |
| 29 | 100 million data points | | | | | | | 1 | 0.19% |
| 30 | analysis 100 million data | | | | | | | 1 | 0.19% |
| 31 | tumour analysis 100 million | | | | | | | 1 | 0.19% |
| 32 | comprehensive tumour analysis 100 | | | | | | | 1 | 0.19% |
| 33 | a comprehensive tumour analysis | | | | | | | 1 | 0.19% |
| 34 | is a comprehensive tumour | | | | | | | 1 | 0.19% |
| 35 | in the laboratory both | | | | | | | 1 | 0.19% |
| 36 | personalised therapy of cancer | | | | | | | 1 | 0.19% |
| 37 | laboratory both tests are | | | | | | | 1 | 0.19% |
| 38 | datar cancer genetics is | | | | | | | 1 | 0.19% |
| 39 | tumour screening test from | | | | | | | 1 | 0.19% |
| 40 | comprehensive tumour screening test | | | | | | | 1 | 0.19% |